This article was released as Pharm Edaily Premium Content on December 19, 2025, at 8:00 AM.
[Seungkwon kim, Edaily reporter] Stocks in South Korea’s pharmaceuticals, biotech and healthcare sector rallied on Dec. 18 led by names tied to new drug development regenerative medicine and bio-manufacturing (ODM/OEM) each backed by distinct growth narratives. Algonomics, OrganoidScience and T&R Biofab were among the notable gainers.
 |
Algonomics stock trend on Dec 18. (image=MP DOCTOR) |
Algonomics Shares Surge on IPO Debut Amid Strong Demand for RNA Gene Therapy Platform
Algonomics surged 300% to close at 90,000 won on its first day of trading on the KOSDAQ, recording a so-called “quadruple” debut a move widely attributed to strong initial demand typical of newly listed shares, combined with upbeat sentiment from its bookbuilding and subscription results.
The company is developing RNA based gene therapies targeting oncology and rare intractable diseases. Investors are focusing on the scalability of its platform a view that the company’s valuation could shift if the platform repeatedly generates candidates through pipeline building and ultimately leads to global co-development or licensing deals.
Key medium to long term watchpoints include clinical data and partnering progress. Volatility could increase around interim clinical readouts, including conference presentations. Additional license-out outcomes if materialized could help shift the “IPO premium” toward an “earnings and contract premium.” At the same time, the market is expected to monitor supply demand factors such as lock up expirations and short-term profit taking after early overheating.
An Algonomics official said the company’s lead oncology gene therapy candidate RZ-001, is progressing smoothly in clinical trials adding that it plans to present interim results at international conferences later this year and in the first half of next year.
 |
OrganoidScience stock trend on Dec 18. |
OrganoidScience Eyes ATORM-C Trial Retry...Highlights ShortTerm Cash Flow via ODISE
OrganoidScience rose 11.7% to 43,750 won, with gains driven by expectations that the company will reattempt clinical entry for ATORM-C, an intestinal organoid based regenerative therapy. The company has indicated it plans to refile an IND application within the month after supplementing additional nonclinical data following a previous IND rejection.
Organoid technology three-dimensional cellular structures is viewed as both an alternative testing platform that can improve drug development efficiency and a potential pathway into regenerative therapies over time. OrganoidScience has highlighted a two track strategy its ATORM regenerative therapy brand and ODISEI, an organoid-based novel material evaluation solution.
ODISEI has been positioned as a near-term cash flow driver as demand could increase in line with efforts to reduce animal testing. The immediate momentum hinges on whether the IND refiling leads to clinical entry with regulatory communication and documentation requirements seen as key variables in a relatively unfamiliar area.
Over the longer term investors are expected to look for progress across clinical advancement outcomes from using such as treatment planning systems and ODISEI’s customer and revenue scalability.
 |
T&R Biofab stock trend on Dec 18. |
T&R Biofab Rides Blisspack Inclusion, Eyes FDA Nod for TnR CFI in Dual Track of Earnings and Approvals
T&R Biofab gained 11.6% to close at 3,780 won. The market cited combined catalysts: expectations for expanded scale following the consolidation of subsidiary Blisspack and anticipation tied to U.S. FDA regulatory momentum for its 3D printed cranial implant TnR CFI.
The company previously disclosed an agreement related to acquiring cosmetics OEM firm Blisspack securing manufacturing infrastructure while outlining a strategy to pursue synergies with its bio and medical businesses.
In medical devices, T&R Biofab said it completed a U.S. FDA 510(k) submission for TnR CFI in late June 2025 and investors have increasingly focused on the timing of a potential outcome as the review period progresses.
Near-term drivers have been summarized as expectations of improved financial stability from Blisspack’s earnings contribution and event driven buying tied to the FDA review timeline. Longer term growth engines include overseas commercialization of regenerative medicinerelated businesses such as bioink 3D bioprinting and organoids as well as biosurgical solutions.
If U.S. clearance becomes a reality the company could shift from a domestic supply centered model to a global partner distribution approach, potentially moving valuation benchmarks from “domestic sales” to “global penetration.”
Oh Hyun-jin, an analyst at Kiwoom Securities, said the company has entered a phase of full-scale growth based on recent performance improvements at Blisspack and a stabilized financial structure.
이 기사의 카테고리는 언론사의 분류를 따릅니다.